Prevena Plus™ Incision Management System Dressings - Acelity KCI PREVENA PLUS Mode D'emploi

Circumferential Dressing Application: Avoid applying the PREVENA PLUS™ Dressing
circumferentially. In cases where the clinician determines that the benefits of applying the PREVENA
PLUS™ Dressing circumferentially outweigh the risk of circulatory compromise, extreme care should
be taken not to stretch or pull the dressing when securing it. Attach the dressing loosely and stabilize
edges with an elastic wrap if necessary. It is crucial to systematically and recurrently palpate distal
pulses and assess distal circulatory status. If circulatory compromise is suspected, discontinue
therapy and remove dressing.
Electrodes or Conductive Gel: Do not allow the PREVENA PLUS™ Dressing to come in contact with
EKG or other electrodes or conductive gels during electronic monitoring or when taking electronic
measurements.
Dressing Components: The PREVENA PLUS™ Dressing contains ionic silver (0.019%). Application of
products containing silver may cause temporary tissue discoloration.
•
Always use PREVENA PLUS™ Dressings and canisters from sterile packages that have not been
opened or damaged.
•
All dressing components and canisters of the PREVENA PLUS™ Incision Management System
are for single use only. Do not re-use any component of this system.
•
To avoid trauma to the skin, do not pull or stretch the adhesive border of the dressing during
application.
Compressive Garments or Dressings: Avoid tight compressive garments or dressings (such as
surgical bras, elastic bandage wraps or abdominal binders) to prevent forcibly pressing the PREVENA
PLUS™ Dressing into soft tissue.
PREVENA PLUS™ INCISION MANAGEMENT SYSTEM DRESSINGS
The PREVENA PLUS™ Incision Management System features PREVENA PLUS™ CUSTOMIZABLE™
Dressings. These dressings contain a skin interface layer that includes 0.019% ionic silver. Silver in
the interface layer of the PREVENA PLUS™ Dressing is not intended to treat infection, but to reduce
bacterial colonization in the fabric. In vitro log reduction tests, conducted without application of
negative pressure, exposed samples of the skin interface layer to a six log challenge of each of
the microorganisms listed below. Following inoculation, samples were tested for microbial counts
immediately (day 0) and after incubation at 90˚F (32˚C) in diluted nutrient broth for 1, 3, 5 and 7 days.
The log reductions from the day 0 values are provided in the table below.
Challenge Organism
Escherichia coli (ATCC 8739)
Pseudomonas aeruginosa (ATCC 09027)
Staphylococcus aureus (ATCC 6538)
Klebsiella pneumonia (ATCC 4352)
Candida albicans (ATCC 10231)
Aspergillus niger (ATCC 16404)
Mean Log Reduction from Day 0
Day 1 Day 3
2.2 4.0
2.0 3.9
1.6 3.6
1.4 1.8
2.5 3.1
2.2 4.1
8
Day 5 Day 7
3.9 4.5
3.5 3.7
3.6 3.5
2.7 3.5
3.2 3.2
4.0 3.6